spacer
home > ict > winter 2018 > promising participation
PUBLICATIONS
International Clinical Trials

Promising Participation

In the history of medical research, the concept of patient centricity is a relatively new one. Until a few years ago, the primary focus of most clinical trials was developing drugs for commercial application. Patients were important and necessary to this process, but only because they represented the human connection to data the development team needed to move a drug candidate or treatment option through the regulatory approval process.

Unsurprisingly, patients who did become involved in clinical trials often felt disrespected and unimportant. As the industry accepted that patients’ generally low levels of satisfaction translated into compliance issues and high dropout rates, as well as broadly negative perceptions of clinical research that contribute to the limited participation rates of today, interest began to rise in assessing and addressing patient concerns.

By the mid-2000s, terms such as ‘patient centricity’ and ‘patientcentric trials’ had begun to find their way into publications and presentations. Although precise definitions vary, the underlying concept from the beginning is that providing patients with more information and greater integration into the trial process will lead to greater patient satisfaction and improved outcomes for sponsors, research centres, and patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Lea Studer is the Senior Vice President of Marketing Communications at SCORR marketing – a full-service marketing firm in the health sciences industry, and the lead organiser for the Bridging Clinical Research and Clinical Healthcare Collaborative. The collaborative was founded to bring together leaders from pharma, biotechnology, CROs, healthcare organisations, advocacy groups, and the FDA to focus on ways to advance healthcare through bridging regulatory, technology, and people and processes.
spacer
Lea Studer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Aptus Clinical enters into a global partnership agreement with Artelo Biosciences

We are delighted to announce that Aptus Clinical has entered into an agreement with Artelo Biosciences to provide clinical development support the re-purposing of its high-potency dual cannabinoid agonist ART27.13 in oncology.
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

SCOPE Europe: Summit for Clinical Ops Executives

16-17 October 2018, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clin ops execs, functional heads, category managers and those responsible for the planning and management of clinical trials in Europe and the Rest of the World.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement